Noah Stansfield

Omidubicel demonstrated neutrophil engraftment a median of 10 days faster than standard UCBT.

The company announced successful neutrophil and platelet engraftment for the first patient dosed.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

All 3 patients remained progression-free at more than 1 year post-treatment.

In preclinical studies, OBX-115 demonstrated improved TIL persistence, potency, and tumor control compared with unengineered TILs.

Reported efficacy data included a WOMAC score reduction at 6 months following a single dose.

Robin Shaw, MD, PhD, Professor of Medicine at the University of Utah and Director of the Nora Eccles Harrison Cardiovascular Research and Training Institute, shared his thoughts on the program.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Patient recruitment for the clinical trial is currently underway at epilepsy centers throughout the US.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A 93% reduction in serum TTR remained consistent in 6 patients at 6 months.

Legend Biotech seeks to prioritize other product candidates in its pipeline.

Two patients reached significantly higher cognitive development ages than seen in natural history 24 months after dosing.

Patients demonstrated a 7-point improvement above pre-treatment baselines on the North Star Ambulatory Assessment at 4 years post-treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A patient showed more than a 50% reduction in N-acetylaspartate (NAA) in brain white matter at 3 months post-treatment.

Improvements were reported in retinal function, visual function, and functional vision at 6 months post-treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

It will be the first AMN clinical study to utilize wearable technology for monitoring patient activity and outcomes.

Benjamin Harrison, BSc, PhD, assistant professor of biochemistry and nutrition at UNE, shared his thoughts on the research.

The hold was related to a serious adverse event of hypomagnesemia in an ongoing phase 2 clinical trial.

A clinical trial evaluating MB-106 in WM is planned under Mustang Bio's new IND.

The phase 1/2 OVATION 2 study is expected to complete enrollment by the third quarter of this year.

All children in the phase 3 SPR1NT study achieved the primary end point of independent sitting.

The treated patient achieved an overall partial response of 72% in tumor regression.

A multisite phase 1 clinical trial for NT-I7 is underway in patients with relapsed/refractory large B-cell lymphoma.

CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).

Among treated patients, 42% achieved 5-year event free survival.